Nephrolithiasis Clinical Trial
Official title:
Pharmacodynamic Evaluation of the ANTICALCIURIC Effect of Hydrochlorothiazide in Dent's Disease
Intrarenal calcifications (nephrocalcinosis) is present in Dent's disease and likely contribute to progression toward renal failure. In order to prevent this complication it is usually proposed to treat affected patients during childhood with high doses of thiazides.
Intrarenal calcifications (nephrocalcinosis) is present in Dent's disease and likely
contribute to progression toward renal failure. In order to prevent this complication it is
usually proposed to treat affected patients during childhood with high doses of thiazides.
Indeed, this class of diuretics is used for years to treat hypertension, can lower urinary
calcium excretion. However the doses usually used are high, are known to be associated with
adverse events such as severe potassium depletion, decrease in blood pressure and
dehydration. The purpose of the study was to test whether lower dose of thiazides would be
better tolerated, with similar efficacy to lower urinary calcium excretion, as previously
demonstrated in other indication such as treatment of hypertension.
Patient recruitment and clinical evaluation Eight subjects with genetically proven Dent's
disease were recruited through a French nationwide network for tubulopathies and were
enrolled between July 2003 and December 2005.
All patients met at least three standard criteria for the disease including hypercalciuria,
low molecular weight proteinuria and one of the following disorders: nephrocalcinosis,
nephrolithiasis, renal failure, aminoaciduria, glucosuria, renal phosphate wasting, or
familial history of Dent's disease. The disease was confirmed in all patients by direct
sequencing of the CLCN5 gene according to Lloyd et al. (25) Patients presenting hyponatremia
(< 135 mM), hypokalaemia (< 3.3 mM), severe fanconi syndrome, or chronic renal failure (GFR
estimated with the Schwartz formula < 30 mL.min-1.1.73m-2) were excluded from the study.
The protocol was approved by the "comité de protection des personnes" (Paris, Hôtel Dieu)
and all subjects and/or their parents gave written informed consent for the participation in
the study.
Sodium restriction test Because a renal loss of sodium was reported in the disease, the
pharmacological study was preceded by a sodium restriction test involving NaCl intake
equivalent to 0.3 mmol/kg BW) and an age-adjusted calcium intake of 1200-1500 mg/day, to
assess the tolerance to sodium depletion and its effect on calcium excretion. Sodium
restriction was stopped after 5 days or when 24h urinary sodium excretion matched
theoretical salt intake. Blood and urine samples were taken in the morning, two hours after
a light calcium-free breakfast and after a 30 minute rest in the supine position on the
first and last days of the low sodium diet determining electrolytes, plasma proteins,
hematocrit, and plasma renin and aldosterone concentrations.
PHARMACOLOGICAL STUDY After completion of the sodium restriction test, the seven remaining
patients entered a three-period, forced titration sequential open-label trial. They were
instructed to follow normal sodium, isocaloric diet, with an age-adjusted calcium intake of
1200 to 1500 mg/d. One patient had a tendency to hypokalaemia (3.3 mM), requiring potassium
chloride salt supplementation before entering the trial.
After a one month run-in phase, the patients received sequentially a low dose (6.25 mg/day),
an intermediate dose (12.5 mg/day), and a high dose (25 mg/day) of hydrochlorothiazide
(HCTZ), each dose being administered for a period of two months. Amiloride (5 mg/day) was
started at the beginning of the study, and continued throughout the sequential trial to
reduce the risk of HCTZ-induced hypokalaemia. For safety reasons, two patients did not
receive the last 25 mg dose of HCTZ because of a body weight (BW) < 25 kg. The last HCTZ
dose was followed by a one month withdrawal period (phase E).
Clinical (blood pressure and BW), biological and hormonal evaluations were conducted at
baseline and at the end of each treatment period, between 9:00 and 10:00 hours, two hours
after a light calcium-free breakfast and a one hour-rest in a reclined position. At the end
of the baseline and washout periods and each treatment period, two successive 24-h urine
collections were obtained, and a morning spot urine sample was collected on the day of
investigation for measurements of urine electrolytes (Na, K, calcium) and creatinine.
Hematocrit, and electrolyte, creatinine, proteins, renin and aldosterone concentrations were
measured in blood samples. Additionally, Blood Pressure, Body Weight and biological
tolerance was assessed 15 days after each increase in the HCTZ dose.
Analytical methods Methods for the determination of plasma sodium, potassium, creatinine,
magnesium, PTH, 25-OH vitamin D, renin, aldosterone and calcitriol levels have been
described elsewhere.
Statistical Methods The effects of sodium restriction and HCTZ on clinical and biological
markers were first evaluated by Friedman's tests. If a global time-effect was significant,
the change between baseline and the last measurement of the treatment period was tested by a
Wilcoxon's paired test. All data are expressed as median range [minimum; maximum], except
otherwise specified. Values of 24h-urine collection of each period used for analyses were
mean of the measurements made on the two consecutive daily collections. Values for a given
24-h collection were excluded from analysis if the creatinine excretion on that collection
varied by more than 15% or the sodium excretion varied by more than 25% from the mean of
values for other collections by that patient.
All analyses were carried out using SAS Statistical Software (Version 8.2, Cary, NC, USA)
and STATVIEW(SAS Institute Inc., Cary NC) and a p value of less than 0.05 was considered to
be significant.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT04746378 -
PRedictive Accuracy of Initial Stone Burden Evaluation.
|
||
Recruiting |
NCT05100017 -
Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure
|
N/A | |
Recruiting |
NCT03692715 -
Antibiotic Prophylaxis Before Shock Wave Lithotripsy
|
Phase 4 | |
Completed |
NCT02547805 -
Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days
|
Phase 2 | |
Completed |
NCT02289755 -
Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria
|
Phase 2 | |
Completed |
NCT01650935 -
Comparison of DASH With Oxalate Restricted Diet on Urine in Recurrent Stone Formers With Hyperoxaluria
|
N/A | |
Completed |
NCT01690039 -
Influence of Polymorphisms in the ATP6V1 Gene of the V-ATPase on the Development of Incomplete Distal Renal Tubular Acidosis
|
||
Completed |
NCT01295879 -
Vitamin D Repletion in Stone Formers With Hypercalciuria
|
Phase 4 | |
Recruiting |
NCT05014178 -
Kidney Sodium Functional Imaging
|
||
Not yet recruiting |
NCT06199102 -
The High Initial Dose of Monitored Vitamin D Supplementation in Preterm Infants.
|
N/A | |
Recruiting |
NCT04374188 -
Efficacy of Ciprofloxacin Therapy in Avoidance of Sepsis in Patient Undergoing Percutanous Nephrolithotomy
|
N/A | |
Recruiting |
NCT04367155 -
Efficacy of Tranexamic Acid on Blood Loss During Percutaneous Nephrolithotomy.
|
N/A | |
Recruiting |
NCT05701098 -
SOUND Pivotal Trial - (Sonomotion stOne comminUtion resoNance ultrasounD)
|
N/A | |
Recruiting |
NCT04389853 -
Mini-PNCL vs fURS in Management of Nephrolithiasis
|
N/A | |
Completed |
NCT03348228 -
Effect of Hydroxycitrate on Urine Chemistry
|
N/A | |
Completed |
NCT05350423 -
Trial Assessing Renal Damage During Ureteroscopy
|
N/A | |
Completed |
NCT03454139 -
Subcostal TAP Block For Percutaneous Nephrolithotomy
|
N/A | |
Recruiting |
NCT02279927 -
Prospective Comparison Between Different Laser Settings for Ureteral \ Kidney Stones Treatment During Ureteroscopy
|
N/A | |
Completed |
NCT02276924 -
Diagnostic Relevance of Laser Confocal Microscopy for the Screening of Upper Urinary Tract Tumors
|
N/A | |
Completed |
NCT00159393 -
Percutaneous Nephrolithotomy: A Registry and Database
|